Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.

Authors :: Boccon-Gibod C
Talbot A
Le Bras F
Frenzel L
Royer B
Harel S
Lombion N
Belhadj K
Cuccuini W
Arnulf B
Source :: British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (3), pp. e73-e76. Date of Electronic Publication: 2020 Feb 03.
Publication Year :: 2020

Subjects :: Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols pharmacology
Bridged Bicyclo Compounds, Heterocyclic pharmacology
Dexamethasone pharmacology
Female
Humans
Male
Middle Aged
Multiple Myeloma pathology
Neoplasm Recurrence, Local
Oligopeptides pharmacology
Sulfonamides pharmacology
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bridged Bicyclo Compounds, Heterocyclic therapeutic use
Dexamethasone therapeutic use
Multiple Myeloma drug therapy
Oligopeptides therapeutic use
Sulfonamides therapeutic use

Full Text Access

Tools